Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label parallel-cohort study of subcutaneous amivantamab regimens in advanced or metastatic solid tumors including EGFR-mutant non-small cell lung cancer
CTR20223263Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of amivantamab in non-small cell lung cancer (NSCLC), Non-small cell lung cancer adenocarcinoma (NSCLC), Nonhematologic neoplasms, sponsored by Janssen Pharmaceutical. Started Feb 2023; status: active.
02
Drugs
amivantamab
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20223263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223263.